临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 179324-69-7

Bortezomib (PS-341)

中文名称: 硼替佐米
CAS号:179324-69-7
分子式: C19H25BN4O4 分子量: 384.24
产品形式: Free Base
研发状态: Recruiting
研发用途: Relapsed/Refractory Immune Thrombocytopenia
研究机构: Seoul National University Hospital
研发日期: July 7 2023
研发阶段: Phase 2
Bortezomib (PS-341, Velcade, LDP-341, MLM341, NSC 681239) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells. Bortezomib (PS-341) inhibits NF-κB and induces ERK phosphorylation to suppress cathepsin B and inhibit the catalytic process of autophagy in ovarian cancer and other solid tumors.

CAS: 1793080-72-4

VX-150

中文名称:(4-(2-(4-氟-2-甲基苯氧基)-4-(三氟甲基)苯甲酰胺)-2-氧苯苷-1(2H)-基)甲基二氢磷酸盐
CAS号:1793080-72-4
分子式: C21H17F4N2O7P 分子量: 516.34
产品形式: Free Base
研发状态: Completed
研发用途: Acute Pain
研究机构: Vertex Pharmaceuticals Incorporated
研发日期: December 12 2018
研发阶段: Phase 2
VX-150 (EOS-62073) is an orally bioavailable pro-drug that rapidly converts into its active moiety, which is a highly selective inhibitor of NaV1.8 relative to the other sodium channel subtypes (>400-fold).

CAS: 1792180-81-4

Ritlecitinib (PF-06651600)

CAS号:1792180-81-4
分子式: C15H19N5O 分子量: 285.34
产品形式: free base
研发状态: Completed
研发用途: Healthy Participants
研究机构: Pfizer
研发日期: September 28 2020
研发阶段: Phase 1
Ritlecitinib (PF-06651600) is a potent and irreversible JAK3-selective inhibitor with an IC50 of 33.1 nM but without activity (IC50 > 10 000 nM) against JAK1, JAK2, and TYK2.

CAS: 1787294-07-8

Remibrutinib (LOU064)

CAS号:1787294-07-8
分子式: C27H27F2N5O3 分子量: 507.53
产品形式: free base
研发状态: Recruiting
研发用途: Chronic Spontaneous Urticaria
研究机构: Novartis Pharmaceuticals; Novartis
研发日期: July 11 2023
研发阶段: Phase 3
Remibrutinib (LOU064) is a potent, highly selective covalent inhibitor of bruton tyrosine kinase (BTK) with IC50 of 1.3 nM, 2.5 nM and 18 nM for BTK, FcγR-induced IL8 and anti-IgM/IL4-induced CD69, respectively. Remibrutinib (LOU064) exhibits an exquisite kinase selectivity due to binding to an inactive conformation of BTK and has the potential for the treatment of autoimmune diseases.

CAS: 178606-66-1

U-104

中文名称:4-[[[(4-氟苯基)氨基]羰基]氨基]苯磺酰胺
CAS号:178606-66-1
分子式: C13H12FN3O3S 分子量: 309.32
产品形式: free base
研发状态: Recruiting
研发用途: Metastatic Pancreatic Ductal Adenocarcinoma
研究机构: British Columbia Cancer Agency; Canadian Cancer Society (CCS); SignalChem Lifesciences Corporation
研发日期: January 10 2019
研发阶段: Phase 1 : Phase 2
U-104 (MST-104, NSC 213841, SLC-0111, WBI-5111) is a potent carbonic anhydrase (CA) inhibitor for CA IX and CA XII with Ki of 45.1 nM and 4.5 nM, respectively, very low inhibition for CA I and CA II.

CAS: 17795-21-0

Allopurinol Sodium

中文名称:1H-吡唑并[3,4-D]嘧啶-4-醇单钠盐
CAS号:17795-21-0
分子式: C5H4N4NaO 分子量: 159.10
产品形式: Sodium Salt
研发状态: Recruiting
研发用途: Gout
研究机构: InventisBio Co. Ltd
研发日期: April 17 2023
研发阶段: Phase 2
Allopurinol Sodium is a xanthine oxidase inhibitor with an IC50 of 7.82±0.12 μM.